NASDAQ:AXGN - AxoGen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$51.90 +0.95 (+1.86 %)
(As of 06/20/2018 11:07 AM ET)
Previous Close$51.50
Today's Range$51.40 - $52.60
52-Week Range$14.30 - $51.70
Volume1,799 shs
Average Volume336,671 shs
Market Capitalization$1.75 billion
P/E Ratio-167.10
Dividend YieldN/A
Beta0.05
AxoGen logoAxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Debt-to-Equity Ratio0.82
Current Ratio3.32
Quick Ratio2.81

Price-To-Earnings

Trailing P/E Ratio-167.10
Forward P/E Ratio-136.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$60.43 million
Price / Sales29.68
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book70.14

Profitability

EPS (Most Recent Fiscal Year)($0.31)
Net Income$-10,440,000.00
Net Margins-18.83%
Return on Equity-61.66%
Return on Assets-21.29%

Miscellaneous

Employees199
Outstanding Shares34,560,000

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) released its earnings results on Monday, April, 30th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.11). The medical equipment provider earned $17.30 million during the quarter, compared to analyst estimates of $17.16 million. AxoGen had a negative return on equity of 61.66% and a negative net margin of 18.83%. The company's revenue was up 41.8% compared to the same quarter last year. View AxoGen's Earnings History.

What price target have analysts set for AXGN?

8 brokerages have issued twelve-month target prices for AxoGen's stock. Their predictions range from $21.00 to $45.00. On average, they anticipate AxoGen's share price to reach $35.5714 in the next twelve months. View Analyst Ratings for AxoGen.

Who are some of AxoGen's key competitors?

Who are AxoGen's key executives?

AxoGen's management team includes the folowing people:
  • Ms. Karen Zaderej, Pres, CEO & Director (Age 56)
  • Mr. Peter J. Mariani, CFO & Principal Accounting Officer (Age 54)
  • Mr. Gregory G. Freitag, Gen. Counsel, Sr. VP of Bus. Devel. & Director (Age 56)
  • Mr. Shawn F. McCarrey, Sr. VP of Sales (Age 60)
  • Mr. Jon S. Gingrich, Chief Commercial Officer (Age 49)

Has AxoGen been receiving favorable news coverage?

Media stories about AXGN stock have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AxoGen earned a media sentiment score of 0.12 on Accern's scale. They also gave news coverage about the medical equipment provider an impact score of 46.12 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are AxoGen's major shareholders?

AxoGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.94%), Opaleye Management Inc. (4.94%), Wells Fargo & Company MN (2.06%), Rock Springs Capital Management LP (1.46%), Lord Abbett & CO. LLC (1.04%) and Next Century Growth Investors LLC (1.02%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Guido J Neels, James E Flynn, Jamie Mark Grooms, John P Engels, Joseph M Mandato, Karen L Zaderej, Peter J Mariani, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Next Century Growth Investors LLC, Opaleye Management Inc., Russell Investments Group Ltd., Cortina Asset Management LLC, Bamco Inc. NY, Eversept Partners LLC, Timpani Capital Management LLC and Millrace Asset Group Inc.. Company insiders that have sold AxoGen company stock in the last year include Guido J Neels, Jamie Mark Grooms, Robert James Rudelius and Shawn F Mccarrey. View Insider Buying and Selling for AxoGen.

Which major investors are buying AxoGen stock?

AXGN stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Eagle Asset Management Inc., Atlantic Trust Group LLC, Lord Abbett & CO. LLC, Lisanti Capital Growth LLC, Citadel Advisors LLC and Rock Springs Capital Management LP. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, John P Engels, Karen L Zaderej and Peter J Mariani. View Insider Buying and Selling for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $51.95.

How big of a company is AxoGen?

AxoGen has a market capitalization of $1.75 billion and generates $60.43 million in revenue each year. The medical equipment provider earns $-10,440,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. AxoGen employs 199 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (AXGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.